SynthesisPloS one2015
Effects of probucol on restenosis after percutaneous coronary intervention: a systematic review and meta-analysis.
Synthesis in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 23 citations in OpenAlex.
- The efficacy of probucol combined with hydration in preventing contrast-induced nephropathy in patients with coronary heart disease undergoing percutaneous coronary intervention: a multicenter, prospective, randomized controlled study.International urology and nephrology · 2018Trial
- Five-year clinical outcomes in patients with diabetes mellitus treated with polymer-free sirolimus- and probucol-eluting stents versus second-generation zotarolimus-eluting stents: a subgroup analysis of a randomized controlled trial.Cardiovascular diabetology · 2016Trial
- Comparative analysis of quality of life post coronary angioplasty and bypass surgery: A follow-up study on cardiac patients.Medicine · 2026Article
- Mendelian randomization reveals probucol's preventive role in Behçet's disease via circulating metabolites.Scientific reports · 2025Article
- Probucol: revisiting as a multifaceted therapeutic agent in atherosclerosis.Frontiers in pharmacology · 2025Review
- Compositional and functional properties of high-density lipoproteins in relation to coronary in-stent restenosis.Archives of medical science : AMS · 2023Article
- Balloon expandable coronary stent materials: a systematic review focused on clinical success.In vitro models · 2022Review
- Diabetes and restenosis.Cardiovascular diabetology · 2022Review
- Protective Effects of Probucol on Different Brain Cells Exposed to Manganese.Neurotoxicity research · 2022Article
- Role of oxidative stress versus lipids in monocrotaline-induced pulmonary hypertension and right heart failure.Physiological reports · 2021Article
- New Evidence of Probucol on Cardiovascular Events.Journal of atherosclerosis and thrombosis · 2021Article
- Vascular Wall Reactions to Coronary Stents-Clinical Implications for Stent Failure.Life (Basel, Switzerland) · 2021Review
- Probucol Protects Neuronal Cells Against Peroxide-Induced Damage and Directly Activates Glutathione Peroxidase-1.Molecular neurobiology · 2020Article
- Effects of Catheterization on Artery Function and Health: When Should Patients Start Exercising Following Their Coronary Intervention?Sports medicine (Auckland, N.Z.) · 2019Review
- Epigallocatechin-3-gallate attenuates neointimal hyperplasia in a rat model of carotid artery injury by inhibition of high mobility group box 1 expression.Experimental and therapeutic medicine · 2017Article
- Polymer-free dual drug-eluting stents evaluated in a porcine model.BMC cardiovascular disorders · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRestenosis after percutaneous coronary intervention (PCI) is a remained clinical problem which limits long-term success of PCI. Although there was recognition that probucol in treating restenosis after percutaneous transluminal coronary angioplasty, the efficacy of probucol on restenosis after stent-implantation is controversial. So this meta-analysis was conducted to investigate the association between probucol and late restenosis.
methodsArticles were assessed by four trained investigators, with divergences resolved by consensus. PubMed, EMBASE, ScienceDirect and the Cochrane Central Register of clinical trials were searched for pertinent studies. Inclusion criteria were random allocated to treatment and a comparison of probucol-treated patients and control patients (not treated with lipid-lowering drug) undergoing PCI.
resultsFifteen studies with 859 subjects were analyzed. Major outcome, binary angiographic restenosis defined as >50% stenosis upon follow-up angiography, was significantly decreased with probucol treatment (RR = 0.59 [0.43, 0.80] among vessels, P = 0.0007; and RR = 0.52 [0.40, 0.68] among patients, P<0.00001). Probucol also increased the minimal luminal diameter (SMD = 0.45 [0.30, 0.61], P<0.00001) and decreased late loss upon follow-up after 6 months (SMD = -0.41 [-0.60, -0.22], P<0.0001). Moreover, there was a significantly lower incidence of major adverse cardiac events (MACE) in the probucol group than control group (RR = 0.69 [0.51, 0.93], P = 0.01).
conclusionProbucol is more than a lipid-lowering drug. It is also effective in reducing the risk of restenosis and incidence of MACE after PCI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.